University of Dundee

Recovery of kidney function in patients treated with maintenance dialysis – a report from the ERA-EDTA Registry

Jakulj, Lily; Kramer, Anneke; Åsberg, Anders; de Meester, Johan; Santiuste de Pablos, Carmen; Helve, Jaakko

Published in:
Nephrology Dialysis Transplantation

DOI:
[10.1093/ndt/gfaa368](https://doi.org/10.1093/ndt/gfaa368)

Publication date:
2021

Licence:
CC BY

Document Version
Peer reviewed version

[Link to publication in Discovery Research Portal](#)

Citation for published version (APA):

Jakulj, L., Kramer, A., Åsberg, A., de Meester, J., Santiuste de Pablos, C., Helve, J., Hemmelder, M. H., Hertig, A., Arici, M., Bell, S., Mercadal, L., Diaz-Corte, C., Palsson, R., Benítez Sánchez, M., Kerschbaum, J., Collart, F., Massy, Z. A., Jager, K. J., & Noordzij, M. (2021). Recovery of kidney function in patients treated with maintenance dialysis – a report from the ERA-EDTA Registry. *Nephrology Dialysis Transplantation*, 36(6), 1078–1087. <https://doi.org/10.1093/ndt/gfaa368>

General rights

Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain.
- You may freely distribute the URL identifying the publication in the public portal.

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Recovery of kidney function in patients treated with maintenance dialysis – a report from the ERA-EDTA Registry

Lily Jakulj¹; Anneke Kramer²; Anders Åsberg³; Johan de Meester⁴; Carmen Santiuste de Pablos^{5,6}; Jaakko Helve⁷; Marc H. Hemmelder⁸; Alexandre Hertig⁹; Mustafa Arici¹⁰; Samira Bell¹¹; Lucile Mercadal^{12,13}; Carmen Diaz-Corte^{14,15}; Runolfur Palsson^{16,17}; Manuel Benitez Sanchez¹⁸; Julia Kerschbaum¹⁹; Frederic Collart²⁰; Ziad A. Massy^{21,22}; Kitty J. Jager²; Marlies Noordzij²

¹ Dianet Dialysis Center/ Department of Internal Medicine and Nephrology, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands; ² ERA-EDTA Registry, Department of Medical Informatics, Amsterdam University Medical Center, University of Amsterdam, Amsterdam Public Health research institute, Amsterdam, The Netherlands; ³ Department of Transplantation Medicine, Oslo University Hospital – Rikshospitalet, Oslo, Norway; ⁴ Department of Nephrology, Dialysis and Hypertension, Dutch-speaking Belgian Renal Registry (NBVN), Sint-Niklaas, Belgium; ⁵ Murcia Renal Registry, Department of Epidemiology, Murcia Regional Health Council, IMIB-Arrixaca, Murcia, Spain; ⁶ CIBER Epidemiológica y Salud Pública (CIBERESP), Spain; ⁷ Finnish Registry for Kidney Diseases and Abdominal Center Nephrology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland; ⁸ Dutch Renal Registry Renine, Nefrovisie foundation, Utrecht, The Netherlands; ⁹ Sorbonne Université, APHP, Kidney Transplantation, Hôpital de la Pitié Salpêtrière, Paris, France; ¹⁰ Department of Nephrology, Faculty of Medicine, Hacettepe University, Ankara, Turkey; ¹¹ Scottish Renal Registry, Meridian Court, ISD Scotland, Glasgow, UK; ¹² INSERM Center for Renal and Cardiovascular Epidemiology, Villejuif, France; ¹³ Department of Nephrology and Renal Transplantation, AP-HP, Hôpital de La Pitié Salpêtrière Hospital, Paris, France; ¹⁴ Nephrology Department, HUCA, Oviedo, Spain; ¹⁵ Red Investigación Renal (REDINREN), Madrid, Spain; ¹⁶ Division of Nephrology, Landspítali-The National University Hospital of Iceland, Reykjavik, Iceland; ¹⁷ Faculty of Medicine, School of Health Sciences, University of Iceland, Reykjavik, Iceland; ¹⁸ Department of Nephrology, Hospital Juan Ramón Jiménez, Huelva, Spain; ¹⁹ Austrian Dialysis and Transplant Registry, Department for Internal Medicine IV - Nephrology and Hypertension, Medical

University Innsbruck, Innsbruck, Austria; ²⁰ French-Belgian ESRD Registry, Brussels, Belgium; ²¹ Division of Nephrology, Ambroise Paré University Hospital, Boulogne-Billancourt, Paris, France; ²² Institut National de la Santé et de la Recherche Médicale (INSERM) Unit 1018 team5, Research Centre in Epidemiology and Population Health (CESP), University of Paris Ouest-Versailles-St Quentin-en-Yveline, Villejuif, France

Short title: Recovery of kidney function in patients on maintenance dialysis in Europe

Correspondence to:

Anneke Kramer

E-mail: a.kramer@amsterdamumc.nl

ABSTRACT

Background. Literature on recovery of kidney function (RKF) in patients with end-stage kidney disease treated with maintenance dialysis (i.e. over 90 days) is limited. We assessed the incidence of RKF and its associated characteristics in a European cohort of dialysis patients.

Methods. We included adult patients from the European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) Registry who started maintenance dialysis in 1997-2016. Sustained RKF was defined as permanent discontinuation of dialysis. Temporary discontinuation of ≥ 30 days (non-sustained RKF) was also evaluated. Factors associated with RKF adjusted for potential confounders were studied using Cox-regression analyses.

Results. RKF occurred in 7,657 (1.8%) of 440,996 patients of whom 71% experienced sustained RKF. Approximately 90% of all recoveries occurred within the first two years after day 91 of dialysis. Of patients with non-sustained RKF, 39% restarted kidney replacement therapy within one year. Sustained RKF was strongly associated with the following underlying kidney diseases (as registered by the treating physician): tubular necrosis (irreversible) or cortical necrosis (adjusted Hazard Ratio [aHR]: 20.4, 95%CI: 17.9-23.1), systemic sclerosis (aHR: 18.5, 95%CI: 13.8-24.7) and hemolytic uremic syndrome (aHR: 17.3, 95%CI: 13.9-21.6). Weaker associations were found for hemodialysis as first dialysis-modality (aHR: 1.5, 95%CI: 1.4-1.6) and dialysis initiation at an older age (aHR: 1.8, 95%CI: 1.6-2.0) or in a more recent time-period (aHR: 2.4, 95%CI: 2.1-2.7).

Conclusions. Definitive discontinuation of maintenance dialysis is a rare and not necessarily an early event. Certain clinical characteristics, but mostly the type of underlying kidney disease, are associated with a higher likelihood of RKF.

Keywords: hemodialysis, maintenance dialysis, peritoneal dialysis, recovery of kidney function

KEY LEARNING POINTS

What is already known about this subject?

- The incidence of recovery of kidney function (RKF) in patients treated with maintenance dialysis varies in the literature, possibly due to varying definitions of ESKD and RKF
- Hence, the incidence might be overestimated due to inclusion of patients with acute kidney injury (AKI) instead of ESKD or by inclusion of patients who could only temporarily discontinue dialysis treatment (i.e. non-sustained RKF)

What this study adds?

- This study shows a 1.2% incidence of sustained RKF in patients who have been treated with maintenance dialysis for at least 90 days
- Sustained RKF is not necessarily an early event, as nearly half of the patients experienced sustained RKF after at least one year of maintenance dialysis
- Sustained RKF is most prevalent in patients with certain underlying primary kidney diseases, such as tubular necrosis (irreversible) or cortical necrosis, systemic sclerosis and hemolytic uremic syndrome.

What impact this may have on practice or policy?

- Clinicians should be vigilant for RKF in patients treated with maintenance dialysis, not only in the first few months after initiation of the treatment.
- This is of particular importance in a patient with an underlying kidney disease which is associated with sustained recovery of kidney function

INTRODUCTION

Although end-stage kidney disease (ESKD) generally describes irreversible kidney failure requiring kidney replacement therapy (KRT), a small percentage of patients treated with maintenance dialysis (i.e. dialysis for more than 90 days) experience recovery of kidney function (RKF). This can result in a reduction of dialysis dose or even permanent discontinuation of dialysis treatment.

Data on the incidence of RKF in patients treated with maintenance dialysis in Europe are limited to small case series (1,2), single-center (3,4) and single-country studies (5). Reports from observational studies and registries in other parts of the world show that RKF occurs in 1.0 to 6.7% of dialysis patients (6-10). However, these studies express large heterogeneity regarding the definitions used for ESKD and RKF, respectively. Several studies describe RKF to occur within the first 90 days of dialysis treatment, thereby probably including a substantial number of patients with acute kidney injury (AKI) rather than ESKD. Moreover, previous studies include both patients with sustained recoveries, i.e. permanent discontinuation of KRT and patients who had to recommence KRT after variable, sometimes very short-lived KRT-free intervals. Hence, literature on the incidence and associated clinical characteristics of definitive discontinuation of maintenance dialysis in patients with ESKD is currently limited to a report from the Australian and New Zealand Dialysis and Transplant (ANZDATA) Registry published in 2009. In that study, RKF was found to occur in 1% of the approximately 40,000 individuals treated with maintenance dialysis between 1963 and 2006 (7).

Therefore, we assessed the incidence of sustained, as well as non-sustained RKF, and its associated demographic and clinical characteristics in a large cohort of patients with ESKD treated with maintenance dialysis in Europe.

MATERIALS AND METHODS

Patient characteristics

Data of patients with ESKD aged 20 years or older who started dialysis as their first KRT modality between 1997 and 2016 and who received maintenance dialysis treatment, i.e. dialysis for at least 90 days, were extracted from the European Renal Association – European Dialysis Transplantation Association (ERA-EDTA) Registry database. Follow-up continued until December 31st, 2017.

The ERA-EDTA Registry annually collects individual data of patients starting KRT from national and regional renal registries in Europe. Methods of data collection and processing are described in detail elsewhere (11). Data from the following 27 registries were included: Austria, Dutch-speaking Belgium, French-speaking Belgium, Bosnia and Herzegovina, Denmark, Finland, France, Greece, Iceland, the Netherlands, Norway, the Spanish regional renal registries of Andalusia, Aragon, Asturias, Basque Country, Cantabria, Castile and León, Castile-La Mancha, Catalonia, Extremadura, Galicia, Community of Madrid, Murcia, Valencia (inclusion until 2015, follow-up until December 31st, 2016); Sweden, UK (England, Northern Ireland and Wales) and UK (Scotland). National and regional registries contributing data to the ERA-EDTA Registry complied with national legislation with regard to ethics committee approval. We extracted the following patient characteristics: age, sex, dialysis modality at onset, dialysis modality at day 91, country of residence and underlying kidney disease, coded as primary renal disease (PRD). The latter was recorded by the responsible physician and classified according to the coding system of the ERA-EDTA (11). We grouped these PRD codes into twenty PRD categories, as shown in Supplementary Table 1. The dataset contained no missing values for month or year of birth, sex, or dialysis modality and in case of PRD, 0.9% of values were missing.

Recovery of kidney function

RKF was defined as a discontinuation of maintenance dialysis while remaining alive for at least 30 days. Sustained RKF was defined as no return to KRT until death or the end of the study period, after

at least 30 days of KRT-free survival. Patients who returned to KRT within the follow-up period after a KRT-free interval of at least 30 days were considered to have experienced non-sustained RKF.

Follow-up

Patients were followed from Day 91 of dialysis treatment until any of the following events: RKF, kidney transplantation, loss to follow-up, death or end of study period (December 31, 2017). As patients were included from December 1996 until 31 December 2015, potential follow-up was at least 2 years.

Statistical analyses

Data are presented as percentages for categorical variables or as means with standard deviation or median with interquartile range (IQR; 25th-75th percentile) for continuous variables. To study differences between groups, P-values were calculated using Chi-square tests for categorical variables and Wilcoxon tests for continuous variables.

We used the cumulative incidence competing risk approach to study time from day 91 of dialysis to RKF, in which kidney transplantation, loss to follow-up, death and end of study period were taken into account as competing events (12). Unadjusted and adjusted Cox regression analyses were used to determine factors associated with RKF. The variables included in the adjusted models were age, sex, year of onset of dialysis, dialysis modality at day 91, underlying kidney disease and country of residence. In addition, we used the cumulative incidence competing risk approach to study time from day 31 after RKF to death, restart of dialysis or kidney transplantation. In all analyses, follow-up time was censored at five years or at the end of the study period (31 December 2017).

To explore trends over time in the occurrence of RKF, the incidence of RKF was evaluated by dividing the number of RKF cases among patients starting dialysis in each year by the total number of incident dialysis patients in that year. As in our dataset 90% of recoveries occurred within two years after the start of maintenance dialysis, we ceased inclusion on December 31st, 2015 to allow sufficient

follow-up time for RKF to occur. For these analyses, we only included data from registries with available data for the complete time-period 1997-2015. The slope of the trends, i.e. the annual percentage change (APC), was computed using Poisson regression as provided by the Joinpoint regression program 4.0.4. Details of this method have been previously described (13). Statistical analyses were performed using SAS software 9.4 or Joinpoint 4.0.4. $P < 0.05$ was considered statistically significant.

RESULTS

Patient characteristics

Our cohort comprised 440,996 patients who started maintenance dialysis (i.e. dialysis for more than 90 days) between 1997 and 2016 (Table 1). A total of 7,657 patients (1.8%) were reported to have experienced RKF that lasted for at least 30 days. The majority of these patients (N=5,465; 71%) experienced sustained RKF. Their characteristics, as well as those of patients with a non-sustained RKF are listed in Table 1.

Patients with sustained RKF were older, more often female and more frequently initiated KRT with hemodialysis, as compared with patients with non-sustained RKF (Table 1). Patients with non-sustained RKF recommenced KRT after various KRT-free intervals; 39% of patients restarted KRT within one year and 60% within two years after discontinuation of maintenance dialysis (Table 1).

Characteristics associated with recovery of kidney function

Underlying kidney disease - After adjustment for age at start of dialysis, sex, treatment modality at day 91, country of residence and time period of dialysis initiation, patients with the following PRD codes had the highest likelihood of experiencing sustained RKF as compared to patients with diabetes mellitus (reference group): tubular necrosis (irreversible) or cortical necrosis (adjusted hazard ratio [aHR] 20.35, 95% CI: 17.89-23.14), systemic sclerosis (aHR 18.50, 95% CI: 13.84-24.72), hemolytic uremic syndrome (HUS) (aHR 17.31, 95% CI: 13.88-21.59), paraproteinemia (aHR 7.96, 95% CI: 7.04-9.01), vasculitis (aHR 5.72, 95% CI: 4.96-6.59) and ischaemic renal disease/cholesterol embolism (aHR 4.15, 95% CI: 3.46-4.98). The lowest likelihood of sustained RKF was found in patients with cystic kidney disease (aHR 0.11, 95% CI: 0.07-0.19) and congenital kidney disease (aHR 0.67, 95% CI: 0.39-1.14). The findings were consistent when patients with non-sustained RKF were included (Table 2).

Other characteristics - Female sex (aHR 1.13, 95% CI: 1.07-1.19), onset of dialysis treatment at age 60-79 years when compared with 20-39 years (aHR 1.77, 95% CI: 1.55-2.02), hemodialysis as a

treatment modality (aHR 1.50, 95% CI: 1.38-1.64) and dialysis initiation in a more recent time period (aHR 2.38, 95% CI: 2.14-2.65) were also significantly associated with a higher likelihood of sustained RKF, although to a lesser extent than the aforementioned underlying kidney diseases (Table 2). These observations were consistent when patients with non-sustained RKF were included, except for patients older than 80 years at the initiation of dialysis (Table 2).

Recovery of kidney function: incidence and trends over time

Figure 1 displays the cumulative incidence of RKF (1.8%) and of the competing events death (48.7%), kidney transplantation (22.6%) and loss to follow-up (0.9%) in the five years from day 91 of dialysis. The distribution of time on maintenance dialysis before RKF is depicted in Figures 2A and 2B. Approximately 90% of all RKF occurred within the first two years after day 91 of dialysis. Median time on maintenance dialysis before non-sustained RKF was 265 days [IQR: 153-510] and 237 days [137-464] for patients with sustained RKF, respectively.

As presented in Figure 3, we observed a statistically significant increase in the incidence of RKF in the years 1997-2007 with an APC of 6.5 (95% CI: 5.1 to 7.9). Between 2007 and 2012 the incidence of RKF was stable over time, and declined in the years 2012-2015 (APC: -10.3 (95% CI: -17.6 to -2.4)). The proportion of patients with a kidney disease with a high likelihood of RKF remained stable over the time period 1997-2015 (data not shown).

The time to RKF varied markedly according to the type of underlying kidney disease (Supplementary Figure 1). Across all PRD categories, the incidence of RKF was highest in the first 9 months after initiation of maintenance dialysis (Figure 2), although patients with vasculitis and ischaemic renal disease/cholesterol embolism showed a more stable, although very low, incidence rate of RKF over time.

After recovery of kidney function: mortality and return to KRT

The cumulative incidence of death and return to KRT in the five years after day 31 of RKF is shown in Figure 4; 55% did not have a subsequent event within the follow-up period, and are thus considered as sustained RKF, 15.7% died, 28.1% recommenced dialysis treatment and 1.2% underwent kidney transplantation. Among the underlying kidney diseases with the highest likelihood of RKF, the percentage of patients who did not restart KRT after RKF was 74% for patients with tubular necrosis (irreversible) or cortical necrosis, 79% for systemic sclerosis, 73% for HUS and 65% for patients with paraproteinemia. However, among patients with vasculitis and ischaemic renal disease/ cholesterol embolism, the proportion with sustained RKF, 59% and 61% respectively, was more in line with the entire group of patients (data not shown).

DISCUSSION

This study shows that permanent discontinuation of maintenance dialysis occurs in 1.2% of ESKD patients in Europe across a variety of underlying kidney diseases, although patients with PRD categories tubular necrosis (irreversible) or cortical necrosis, systemic sclerosis and HUS have the highest likelihood of RKF. More than half of the sustained RKF occurred within one year after day 91 of dialysis, showing that sustained RKF is not necessarily an early event. Moreover, the time point at which RKF occurred was found to differ between the types of underlying kidney disease.

Although the observed incidence of RKF is in line with the average of 1% reported in case series and registries in 2000-2013 (9), these former reports display a large heterogeneity in definitions of ESKD, and follow-up time and thereby observed duration of RKF. A recent study that included 194,000 individuals in the US Medicare ESRD program found sustained dialysis-independent RKF to occur in > 5% of patients, primarily in the first two months after initiation of dialysis (8). That study was limited by a follow-up time of 2 years at most and included all patients who started dialysis instead of only those remaining on dialysis after 91 days, thereby likely comprising a substantial number of patients who potentially became dialysis-independent by recovering from AKI (8). By exclusive inclusion of patients with ESKD as currently defined (14), we have attempted to minimize the possibility of AKI underlying the temporary need for KRT. In other smaller studies in patients with ESKD defined as such, incidence of RKF varied from 0.8 to 4% (3,6,7,15). Of these, the study by MacDonald and coworkers of the ANZDATA Registry was the largest and most comparable with the present study, reporting RKF to occur in 1.1% of the 15,912 individuals treated with peritoneal dialysis (PD) and 1.0% of 23,658 patients treated with hemodialysis (HD) between 1963 and 2006 (7). In that study, RKF occurred after approximately one year. Twenty-one percent of recovered patients died within a year after RKF; 57% returned to KRT and 22% were alive with dialysis-independent kidney function at the end of that study. By contrast, we found a lower mortality of 15.7% after five years, with a substantially greater number of recovered patients (55%) who did not return to KRT until end of follow-up. Moreover, merely 28% of recovered patients returned to KRT in our study, as compared to 57% in the ANZDATA Registry (7). Patient characteristics were quite similar between

our current study and that of the ANZDATA Registry. The observed differences in dialysis-free survival after RKF are not likely to be explained by the longer follow-up time in that study, as in our study, merely 1-2% of the patients with a non-sustained RKF required restart of KRT after five years of dialysis discontinuation. Hence, this relatively small number of patients would be insufficient to fully explain the difference. Other potential explanations are geographical differences in treatment strategies or the larger cohort and the more recent era in our study. Although the rate of RKF in the ANZDATA Registry did not change when analyses were restricted to patients starting dialysis from 1996 (7), we did find an increase in the incidence of RKF over time, which was significant for the years 1997-2007. This trend was also observed in the USRDS database (17,18) and in a smaller single country study (4). Whether the observed rise in incidence of RKF over time merely reflects changes in coding practices by physicians, variations over time in the practice of early versus late start of dialysis, or true increments by means of improved treatment strategies for certain kidney diseases, remains to be established. Finally, we observed a decline in the incidence of RKF in the years 2012-2015, however additional data over a longer period of time are needed to confirm whether this trend is truly significant.

Several studies have shown that the underlying kidney disease is the most important factor associated with RKF (6,7,15,18,19). This is in line with our findings, as patients with PRD codes tubular necrosis (irreversible) or cortical necrosis, systemic sclerosis and HUS had the highest likelihood of RKF, followed by patients with paraproteinemia, vasculitis and ischaemic renal disease/cholesterol embolism. By contrast, patients with congenital or cystic kidney disease expressed the lowest likelihood of RKF. This also applied to patients with diabetes mellitus. Our finding that the PRD categories systemic sclerosis, tubular necrosis (irreversible) or cortical necrosis, HUS and paraproteinemia were associated with a higher incidence of RKF is consistent with previous reports (6,7,15). This is also in line with clinical practice experience, as patients with these underlying kidney diseases often present with acute kidney injury with possible treatment options to restore kidney function (20). In a subgroup analysis of auto-immune diseases in the ANZDATA Registry (6,7) RKF was associated with microscopic polyangiitis, consistent with our observed association between

vasculitis and a higher likelihood of RKF. In turn, we could confirm their observed positive association between interstitial nephritis and RKF (7), although in our analyses the association was not as strong as previously reported (data not shown). Multiple myeloma (21,22), systemic sclerosis (23-24) and HUS (5) were associated with a higher likelihood of RKF in earlier smaller observational studies, which is also consistent with our current findings.

In the present study, female sex, hemodialysis, onset of dialysis at an older age and initiation of dialysis in a more recent era were also associated with a higher likelihood of RKF, although to a far lesser extent than the underlying kidney disease. A possible explanation for the observed negative association between age at dialysis onset and the occurrence of RKF is that in younger patients, congenital, cystic and diabetic disease might be overrepresented. These kidney diseases are associated with a low likelihood of RKF. In addition, older patients might be more likely to experience pre-ESKD AKI, due to a higher prevalence of heart failure or cardio-renal syndrome in these older patients. Age and sex have been associated with RKF in observational studies employing different definitions of ESKD and RKF (9,10). However, in the ANZDATA Registry, after adjustment for comorbidities, smoking and body mass index, there was no statistically significant independent association of RKF with age, sex, or type of comorbidity (6). Finally, we found a higher likelihood of RKF in patients treated with hemodialysis as compared to peritoneal dialysis. A possible explanation for this association might be that patients who become dialysis-dependent due to AKI, whether or not superimposed on an underlying kidney disease, usually start on HD rather than PD. Existing data comparing RKF in HD and PD are inconclusive (10). The ANZDATA Registry showed that dialysis modality had no relationship with the rate, timing, or durability of the RKF (7). Hence, the difference with our findings is either explained by more extensive adjustment for possible confounders in that study or by geographical and historical differences between our study and those of the ANZDATA Registry (7).

Our study has several limitations. Firstly, information on race, body mass index, comorbidities (heart failure or cardio-renal syndrome in particular), use of medication, such as renin-angiotensin-aldosterone system-inhibitors, non-steroidal anti-inflammatory drugs or immunosuppressive drugs,

type of vascular access, delivered dialysis dose and measurements of residual kidney function at time of dialysis onset or during maintenance dialysis were unavailable. Due to the lack of these data, we could not adjust our analyses for these potentially relevant factors. Secondly, although we exclusively included patients with ESKD, it is possible that a considerable number of included patients became maintenance dialysis-dependent due to AKI rather than progression of their kidney disease. In a retrospective cohort of 47,341 incident hemodialysis patients, 54% had experienced at least one AKI event in the two years prior to ESKD (25). Moreover, in that study, 1-year all-cause mortality was higher in the pre-ESKD AKI group as compared to the non-AKI group (adjusted odds ratio 1.36; 95% CI 1.30-1.42). Since we do not have data on pre-ESKD AKI events, presence of cardio-renal syndrome, use of nephrotoxic medications, or serum creatinine slopes in the time prior to initiation of KRT, it is impossible to investigate to what extent possible pre-ESKD AKI-events have influenced the observed incidence of RKF or mortality in our study. Furthermore, within the ERA-EDTA Registry, we can only rely on the kidney disease as coded by the treating physicians, according to pre-specified, not necessarily histologically proven, PRD codes. Hence, it is conceivable that patients and particularly those registered with PRD code: ‘Tubular necrosis (irreversible) or cortical necrosis’ indeed experienced AKI. Notwithstanding, approximately half of these patients experienced RKF after one year of dialysis treatment. This supports the message of the current study that AKI, whether or not superimposed on an underlying PRD, might still result in RKF even after a long duration of maintenance dialysis.

Thirdly, as information on patients who permanently discontinued KRT might be incomplete, the mortality rate after permanent discontinuation of KRT (sustained RKF) might be underestimated. Yet, we consider it unlikely that many patients who were qualified as having experienced sustained RKF, discontinued dialysis in order to pursue conservative medical or palliative care. Finally, due to the observational design of this cohort study, it is impossible to study causal inference.

Previous reports on RKF have suggested to postpone kidney transplantation in patients on maintenance dialysis with certain types of underlying kidney disease associated with a high likelihood of RKF (3,5). Until more specific markers of improvement in kidney function can be identified to

guide management, we do not advocate postponing kidney transplantation in patients with kidney disease associated with a high likelihood of RKF, based on our current findings with aforementioned limitations or on other available literature on this subject to date.

In conclusion, our study shows that permanent discontinuation of maintenance dialysis in patients with ESKD is an uncommon event, which occurs across a variety of underlying kidney pathology, although patients with certain types of kidney disease have the highest likelihood of RKF in this setting. In addition, sustained RKF is not necessarily an early event. Therefore, although rare, clinicians should be vigilant of the occurrence of RKF, even in patients who have been treated with maintenance dialysis for a longer period of time.

CONFLICT OF INTEREST STATEMENT

None of the authors has any relevant disclosures or potential conflicts of interest to declare.

ACKNOWLEDGEMENTS

We would like to thank the patients and the staff of the dialysis and transplant units for contributing the data via their national and regional renal registries. Furthermore, we gratefully acknowledge the following registries and persons for their contribution of the data: Austrian Dialysis and Transplant Registry [OEDTR] (R. Kramar); Dutch speaking Belgian Society of Nephrology [NBVN] (M. Couttenye and F. Schroven); French speaking Belgian Society of Nephrology [GNFB] (JM. des Grottes); Renal Registry Bosnia and Herzegovina (H. Resić, B Jakovljevic, and M Tomić); Danish Nephrology Registry [DNS] (J.G. Heaf); Finnish Registry for Kidney Diseases (P. Finne and P.H. Groop); France: The Epidemiology and Information Network in Nephrology [REIN] (M. Lassalle and C. Couchoud); Hellenic Renal Registry (G. Moustakas); Icelandic End-Stage Renal Disease Registry; Norwegian Renal Registry (A.V. Reisæter); Swedish Renal Registry [SRR] (K.G. Prütz, M. Stendahl, M. Evans, S. Schön, T. Lundgren, and M. Segelmark); Dutch Renal Registry [RENINE] (L. Heuveling and S. Vogelaar); UK Renal Registry (All the staff of the UK Renal Registry and of the renal units submitting data); Scottish Renal Registry [SRR] (All of the Scottish renal units); and the regional registries of Andalusia [SICATA] (P. Castro de la Nuez (on behalf of all users of SICATA)), Aragon (F. Arribas Monzón, J.M. Abad Diez, and J.I. Sanchez Miret), Asturias (P. Beltrán, J.R. Quirós, and RERCA Working Group), Basque country [UNIPAR] (Á. Magaz, J. Aranzabal, M. Rodrigo, and I. Moina), Cantabria (J.C. Ruiz San Millán, O. Garcia Ruiz, and C. Piñera Haces), Castile and León (M.A. Palencia García), Castile-La Mancha (G. Gutiérrez Ávila and I. Moreno Alía), Catalonia [RMRC] (E. Arcos, J. Comas, and J. Tort), Community of Madrid (M.I. Aparicio de Madre), Extremadura (All the renal units (Nephrology and Dialysis)), Galicia (E. Bouzas-Caamaño), Renal Registry of the Region of Murcia (I. Marín Sánchez), and Valencian region [REMRENAL] (M. Ferrer Alamar, N. Fuster Camarena and J. Pérez Penadés); and the other ERA-EDTA registry committee members not mentioned above for their advice in the analysis and the drafting of this paper: C. Zoccali, P. Ambühl, J. Harambat, L. Mercadal, M. Nordio, S.S. Sørensen, and E. Vidal; and R. Boenink in the AMC Registry office for data collection and management.

FUNDING

The ERA-EDTA Registry is funded by the European Renal Association-European Dialysis and Transplant Association (ERA-EDTA).

AUTHORS' CONTRIBUTIONS

This article was written by L. Jakulj, A. Kramer, A. Åsberg, J. de Meester, C. Santiuste de Pablos, J. Helve, M. Hemmelder, A. Hertig, M. Arici, S. Bell, L. Mercadal, C. Diaz-Corte, R. Palsson, M. Benitez Sanchez, J. Kerschbaum, F. Collart, Z.A. Massy, K.J. Jager, and M. Noordzij on behalf of the ERA-EDTA Registry which is an official body of the ERA-EDTA (European Renal Association – European Dialysis and Transplant Association).

Table of Contents for the Supplementary Material

Supplementary Table 1. Primary renal disease codes and groups

Supplementary Figure 1. Time to sustained and non-sustained recovery of kidney function (RKF)

REFERENCES

1. De Lind van Wijngaarden RA, Hauer HA, Wolterbeek R, Jayne DR, Gaskin G, Rasmussen N, Noël LH, Ferrario F, Waldherr R, Bruijn JA, Bajema IM, Hagen EC, Pusey CD. Chances of renal recovery for dialysis-dependent ANCA-associated glomerulonephritis. *J Am Soc Nephrol* 2007; 18(7): 2189-2197
2. Hruskova Z, Pippias M, Stel VS, Abad-Diez JM, Benítez Sanchez M, Caskey FG, Collart F, De Meester J, Finne P, Heaf JG, Magaz A, Palsson R, Varberg Reisæter A, Salama AD, Segelmark M, Traynor JP, Massy ZA, Jager KJ, Tesar V. Characteristics and Outcomes of Patients With Systemic Sclerosis (Scleroderma) Requiring Renal Replacement Therapy in Europe: Results From the ERA-EDTA Registry. *Am J Kidney Dis* 2019; 73(2): 184-193
3. Siddiqui S, Norbury M, Robertson S, Almond A, Isles C: Recovery of renal function after 90 d on dialysis: implications for transplantation in patients with potentially reversible causes of renal failure. *Clin Transplant* 2008; 22(2): 136–140
4. Letachowicz K, Madziarska K, Letachowicz W, Krajewska M, Penar J, Kusztal M, Golebiowski T, Weyde W, Klinger M: The possibility of renal function recovery in chronic hemodialysis patients should not be overlooked: Single center experience. *Hemodialysis International* 2016; 20(2): E12–E14
5. Fehrman-Ekholm I, Bergenhag AC, Heimbürger O, Schön S: Recovery of Renal Function after One-Year of Dialysis Treatment: Case Report and Registry Data. *Int J Nephrol* 2010; 17: 817836
6. Craven AM, Hawley CM, McDonald SP, Rosman JB, Brown FG, Johnson DW: Predictors of renal recovery in Australian and New Zealand end-stage renal failure patients treated with peritoneal dialysis. *Perit Dial Int* 2007; 27(2): 184-191
7. MacDonald JA, McDonald SP, Hawley CM, Rosman J, Brown F, Wiggins KJ, Bannister K, Johnson DW: Recovery of renal function in end-stage renal failure—comparison between peritoneal dialysis and haemodialysis. *Nephrol Dial Transplant* 2009; 24: 2825–2831

8. Mohan S, Huff E, Wish J, Lilly M, Chen SC, McClellan WM: Recovery of Renal Function among ESRD Patients in the US Medicare Program. *PLoS One* 2013; 8(12): e83447
9. Piccoli GB, Guzzo G, Vigotti FN, Scognamiglio S, Consiglio V, Aroasio E, Gonella S, Castelluccia N, Mauro G, Colombi N: Chronic dialysis discontinuation: a systematic narrative review of the literature in the new millennium. *Int J Artif Organs* 2014; 37(7): 556-562
10. Chu JK, Folkert VW: Renal Function Recovery in Chronic Dialysis Patients. *Seminars in Dialysis* 2010; 23(6): 606-613
11. ERA-EDTA Registry: ERA-EDTA Registry Annual Report 2016. Amsterdam UMC, location AMC, Department of Medical Informatics, Amsterdam, the Netherlands, 2018.
<https://www.era-edta-reg.org>.
12. Noordzij M, Leffondré K, van Stralen KJ, Zoccali C, Dekker FW, Jager KJ: When do we need competing risks methods for survival analysis in nephrology? *Nephrol Dial Transplant* 2013; 28(11): 2670-2677
13. Kramer A, Stel V, Zoccali C, Heaf J, Ansell D, Grönhagen-Riska C, Leivestad T, Simpson K, Pálsson R, Postorino M, Jager K: An update on renal replacement therapy in Europe: ERA-EDTA Registry data from 1997 to 2006. *Nephrol Dial Transplant* 2009; 24(12): 3557-3566
14. KDIGO CKD Work Group: Chapter 1: definition and classification of CKD. *Kidney Int Suppl* 2013; 3: 19–62
15. Rottembourg J. Residual renal function and recovery of renal function in patients treated by CAPD. *Kidney Int* 1993; Suppl 40: S106-S110
16. Wright S, Klausner D, Baird B, Williams ME, Steinman T, Tang H, Ragasa R, Goldfarb-Rumyantzev AS: Timing of dialysis initiation and survival in ESRD. *Clin J Am Soc Nephrol* 2010; 5(10): 1828-1835
17. Heung M, Campbell F, Kalbfleisch J, Shearon T, Ashby V: Characteristics of and outcomes for patients recovering from ESRD. *J Am Soc Nephrol* 2010; 21: 717A

18. Lindblad AS, Nolph KD: Recovery of renal function in continuous ambulatory peritoneal dialysis: a study of National CAPD Registry data. *Perit Dial Int* 1992; 12(1): 43-47
19. Pichette V, Quérin S, Desmeules M, Ethier J, Copleston P: Renal function recovery in end-stage renal disease. *Am J Kidney Dis* 1993; 22(3): 398-402
20. Levey AS, James MT: Acute Kidney Injury. *Ann Intern Med* 2017; 167(9): ITC66-ITC80
21. Bladé JI, Fernández-Llama P, Bosch F, Montolíu J, Lens XM, Montoto S, Cases A, Darnell A, Rozman C, Montserrat E: Renal failure in multiple myeloma: presenting features and predictors of outcome in 94 patients from a single institution. *Arch Intern Med* 1998; 158(17): 1889-1893
22. Coward RA, Mallick NP, Delamore IW: Should patients with renal failure associated with myeloma be dialysed? *Br Med J (Clin Res Ed)* 1983; 287(6405): 1575-1578
23. Steen VD, Medsger TA Jr: Long-term outcomes of scleroderma renal crisis. *Ann Intern Med* 2000; 133(8): 600-603
24. Penn H, Howie AJ, Kingdon EJ, Bunn CC, Stratton RJ, Black CM, Burns A, Denton CP: Scleroderma renal crisis: patient characteristics and long-term outcomes. *QJM* 2007; 100(8):485-494
25. Lee T, Shah S, Leonard A.C., Parikh P, Thakar C.V: Acute Kidney Injury before Dialysis Initiation Predicts Adverse Outcomes in Hemodialysis Patients. *Am J Nephrol* 2018;47:427–434

Table 1. Characteristics of patients on maintenance dialysis who started treatment between 1997 and 2016 and those that experienced recovery of kidney function

	Maintenance Dialysis N=440,996	Sustained RKF N=5,465	Non-sustained RKF N=2,192	P-value
Sex, N (%)				
Females	163,188 (37.0)	2,239 (41.0)	761 (34.7)	
Males	277,808 (63.0)	3,226 (59.0)	1,431 (65.3)	<0.001
Age at onset in years, median (IQR)	67.9 (55.8 - 76.5)	69.7 (59.6 - 77.0)	64.2 (52.0 - 72.2)	<0.001
Age categories, N (%)				
20-39y	33,878 (7.7)	260 (4.8)	239 (10.9)	<0.001
40-59y	10,8671 (24.6)	1,131 (20.7)	628 (28.6)	<0.001
60-79y	232,786 (52.8)	3,215 (58.8)	1,189 (54.2)	<0.001
80-100y	65,661 (14.9)	859 (15.7)	136 (6.2)	<0.001
PRD group, N (%)				
Diabetes mellitus type 1 and 2	106,100 (24.1)	603 (11.0)	374 (17.1)	<0.001
Cause unknown or missing	87,772 (19.9)	1,247 (22.8)	325 (14.8)	<0.001
Hypertension	63,366 (14.4)	530 (9.7)	299 (13.6)	<0.001
Cystic kidney disease	28,925 (6.6)	17 (0.3)	40 (1.8)	<0.001
Glomerulonephritis	28,570 (6.5)	442 (8.1)	211 (9.6)	0.029
Pyelonephritis/infectious	24,718 (5.6)	295 (5.4)	136 (6.2)	0.166
Renovascular disease	18,553 (4.2)	291 (5.3)	101 (4.6)	0.198
IgA nephropathy	13,300 (3.0)	120 (2.2)	53 (2.4)	0.554
Paraproteinemia	11,461 (2.6)	451 (8.3)	107 (4.9)	<0.001
TIN and drug-induced	11,277 (2.6)	246 (4.5)	81 (3.7)	0.115
Vasculitis	9,514 (2.2)	295 (5.4)	164 (7.5)	<0.001
FSGS with nephrotic syndrome	7,456 (1.7)	40 (0.7)	29 (1.3)	0.013
Ischaemic renal disease/cholesterol embolism	6,440 (1.5)	158 (2.9)	53 (2.4)	0.253
Kidney tumour/trauma/loss	5,652 (1.3)	53 (1.0)	15 (0.7)	0.229

Congenital kidney disease	4,926 (1.1)	14 (0.3)	24 (1.1)	<0.001
Membranous nephropathy	4,114 (0.9)	44 (0.8)	25 (1.1)	0.160
Miscellaneous	3,689 (0.8)	70 (1.3)	32 (1.5)	0.537
Tubular necrosis (irreversible) or cortical necrosis	3,450 (0.8)	404 (7.4)	86 (3.9)	<0.001
HUS	1,167 (0.3)	95 (1.7)	30 (1.4)	0.249
Systemic sclerosis	546 (0.1)	50 (0.9)	7 (0.3)	0.006
KRT modality at day 91, N (%)				
HD	361,549 (82.0)	4,821 (88.2)	1,707 (77.9)	<0.001
PD	79,447 (18.0)	644 (11.8)	485 (22.1)	<0.001
KRT modality at RKF, N (%)				
HD		4,702 (86.0)	1,680 (76.6)	<0.001
PD		753 (13.8)	508 (23.2)	<0.001
Unknown		10 (0.2)	4 (0.2)	0.996
Duration of RKF, N (%)				
30-90 days			264 (12.0)	
90-365 days			590 (26.9)	
1-2 years			455 (20.8)	
2-5 years			614 (28.0)	
>5 years			269 (12.3)	
KRT modality after non-sustained RKF, N (%)				
HD			1,749 (79.8)	
PD			347 (15.8)	
Transplantation			96 (4.4)	

PRD: primary renal disease; KRT: kidney replacement therapy; HD: hemodialysis; PD: peritoneal dialysis; FSGS: focal segmental glomerulosclerosis; HUS: hemolytic uremic syndrome; TIN: tubulo-interstitial nephritis; RKF: recovery of kidney function; IQR: interquartile range. Paraproteinemia includes multiple myeloma, light chain nephropathy and amyloidosis. For categorical variables p-values were calculated with chi-square tests, for continuous variables the Wilcoxon test was applied. Percentages are column percentages. P-value comparing sustained and non-sustained RKF

Table 2. Unadjusted and adjusted hazard ratios with 95% CI for 1) all recovery of kidney function (RKF) and 2) sustained RKF

		All RKF			Sustained RKF		
	N at risk	RKF, N (%)	Unadjusted HR (95%CI)	Adjusted HR (95% CI)	RKF, N (%)	Unadjusted HR (95%CI)	Adjusted HR (95% CI)
Sex							
Male	277,808	4607 (1.7)	1 (ref)	1 (ref)	3185 (1.1)	1 (ref)	1 (ref)
Female	163,188	2954 (1.8)	1.08 (1.03-1.13)	1.04 (1-1.09)	2201 (1.3)	1.17 (1.11-1.23)	1.13 (1.07-1.19)
KRT modality at day 91							
HD	361,549	6450 (1.8)	1.27 (1.19-1.35)	1.21 (1.13-1.29)	4757 (1.3)	1.65 (1.52-1.79)	1.50 (1.38-1.64)
PD	79,447	1111 (1.4)	1 (ref)	1 (ref)	629 (0.8)	1 (ref)	1 (ref)
Age start (years)							
20-39 years	33,878	495 (1.5)	1 (ref)	1 (ref)	257 (0.8)	1 (ref)	1 (ref)
40-59 years	108,671	1735 (1.6)	1.02 (0.93-1.13)	1.18 (1.07-1.31)	1111 (1.0)	1.27 (1.11-1.45)	1.46 (1.27-1.67)
60-79 years	232,786	4342 (1.9)	1.21 (1.10-1.32)	1.27 (1.16-1.40)	3165 (1.4)	1.70 (1.50-1.93)	1.77 (1.55-2.02)
80-100 years	65,661	989 (1.5)	1.05 (0.94-1.17)	1.05 (0.94-1.18)	853 (1.3)	1.75 (1.52-2.01)	1.69 (1.46-1.95)
PRD group							
Diabetes mellitus type 1 and 2	106,100	965 (0.9)	1 (ref)	1 (ref)	592 (0.6)	1 (ref)	1 (ref)
Cause unknown or missing	87,772	1552 (1.8)	2.01 (1.86-2.18)	2.28 (2.10-2.47)	1230 (1.4)	2.60 (2.36-2.87)	2.90 (2.63-3.20)
Hypertension	63,366	819 (1.3)	1.42 (1.29-1.56)	1.39 (1.27-1.53)	523 (0.8)	1.48 (1.31-1.66)	1.45 (1.29-1.63)

Cystic kidney disease	28,925	57 (0.2)	0.22 (0.17-0.28)	0.22 (0.17-0.29)	17 (0.1)	0.10 (0.06-0.17)	0.11 (0.07-0.19)
Glomerulonephritis	28,570	650 (2.3)	2.51 (2.27-2.77)	2.75 (2.48-3.04)	441 (1.5)	2.78 (2.46-3.14)	3.25 (2.87-3.68)
Pyelonephritis/ infectious	24,718	419 (1.7)	1.85 (1.65-2.07)	2.07 (1.84-2.32)	284 (1.1)	2.04 (1.77-2.35)	2.31 (2.01-2.66)
Renovascular disease	18,553	381 (2.1)	2.33 (2.07-2.63)	2.09 (1.85-2.36)	283 (1.5)	2.82 (2.45-3.25)	2.42 (2.09-2.80)
IgA nephropathy	13,300	171 (1.3)	1.50 (1.28-1.77)	1.61 (1.36-1.89)	118 (0.9)	1.69 (1.39-2.06)	2.00 (1.64-2.44)
Paraproteinemia	11,461	553 (4.8)	6.37 (5.73-7.07)	6.22 (5.60-6.91)	447 (3.9)	8.35 (7.39-9.45)	7.96 (7.04-9.01)
TIN and drug-induced	11,277	326 (2.9)	3.25 (2.86-3.68)	3.03 (2.67-3.43)	245 (2.2)	3.98 (3.43-4.62)	3.77 (3.24-4.37)
Vasculitis	9,514	454 (4.8)	5.38 (4.81-6.01)	5.37 (4.80-6.01)	291 (3.1)	5.62 (4.88-6.47)	5.72 (4.96-6.59)
FSGS with nephrotic syndrome	7,456	69 (0.9)	1.01 (0.79-1.30)	1.06 (0.83-1.36)	40 (0.5)	0.96 (0.70-1.32)	1.07 (0.77-1.47)
Ischaemic renal disease/cholesterol embolism	6,440	207 (3.2)	3.69 (3.18-4.29)	3.51 (3.00-4.09)	154 (2.4)	4.47 (3.74-5.34)	4.15 (3.46-4.98)
Kidney tumour/trauma/loss	5,652	67 (1.2)	1.34 (1.05-1.72)	1.27 (0.99-1.63)	52 (0.9)	1.70 (1.28-2.26)	1.56 (1.17-2.07)
Congenital kidney disease	4,926	38 (0.8)	0.87 (0.63-1.20)	0.96 (0.70-1.34)	14 (0.3)	0.52 (0.31-0.89)	0.67 (0.39-1.14)
Membraneous nephropathy	4,114	67 (1.6)	1.75 (1.37-2.24)	1.91 (1.49-2.45)	43 (1.0)	1.83 (1.35-2.50)	2.02 (1.48-2.76)
Miscellaneous	3,689	100 (2.7)	3.06 (2.49-3.76)	3.14 (2.56-3.86)	68 (1.8)	3.39 (2.64-4.35)	3.63 (2.82-4.67)
Tubular necrosis (irreversible) or cortical necrosis	3,450	485 (14.1)	18.44 (16.54-20.57)	15.87 (14.21-17.73)	400 (11.6)	24.71 (21.76-28.05)	20.35 (17.89-23.14)
HUS	1,167	124 (10.6)	12.52 (10.39-15.10)	12.44 (10.29-15.04)	94 (8.1)	15.46 (12.43-19.21)	17.31 (13.88-21.59)
Systemic sclerosis	546	57 (10.4)	12.92 (9.89-16.88)	12.76 (9.76-16.69)	50 (9.2)	18.43 (13.81-24.59)	18.50 (13.84-24.72)
Onset of KRT							
1997-2001	59,042	777 (1.3)	1 (ref)	1 (ref)	428 (0.7)	1 (ref)	1 (ref)

2002-2006	98,103	1576 (1.6)	1.2 (1.10-1.31)	1.37 (1.26-1.49)	1026 (1.0)	1.42 (1.27-1.59)	1.57 (1.40-1.76)
2007-2011	133,838	2578 (1.9)	1.42 (1.31-1.54)	1.68 (1.55-1.83)	1782 (1.3)	1.79 (1.61-1.99)	2.04 (1.83-2.27)
2012-2016	150,013	2630 (1.8)	1.40 (1.29-1.51)	1.67 (1.53-1.81)	2150 (1.4)	2.07 (1.87-2.30)	2.38 (2.14-2.65)

Hazard ratio (HR) adjusted for age at onset of dialysis, sex, year of dialysis onset, treatment modality at day 91, underlying kidney disease (PRD) and country of residence;

KRT: kidney replacement therapy; HD: hemodialysis; PD: peritoneal dialysis; PRD: primary renal disease; FSGS: focal segmental glomerulosclerosis; HUS: hemolytic uremic syndrome; TIN: tubulo-interstitial nephritis. Patient numbers differ slightly from those shown in Table 1, as the Cox-regression analyses included only patients with a RKF within five years after initiation of dialysis. Percentages are row percentages.

FIGURE 1: Cumulative incidence of recovery of kidney function and other competing events during five years after initiation of maintenance dialysis treatment.

FIGURE 2A AND B: Time between day 91 of dialysis treatment and sustained and non-sustained recovery of kidney function (RKF) displayed as total patient numbers (A) and as a percentage of all patients with RKF (B).

FIGURE 3: Incidence of recovery of kidney function with annual percent change within two years after initiation of maintenance dialysis.

Incidence of recovery of kidney function (RKF) within two years after start of maintenance dialysis as a percentage of the total incident population on maintenance dialysis in that year. This includes patients with both sustained and non-sustained RKF. Inclusion was limited to the years 1997-2016 and follow-up to 31 December 2017 in order to ensure sufficient follow-up time for RKF to occur, as 90% of all recoveries occurred within 2 years. Only data from registries providing data for the complete time-period were included: Austria, Dutch-speaking Belgium, French-speaking Belgium, Denmark, Finland, Greece, Iceland, the Netherlands, Norway, the Spanish regional renal registries of Andalusia, Asturias, Basque Country, Cantabria and Catalonia), Sweden and United Kingdom (Scotland); APC: annual percent change

FIGURE 4: Cumulative incidence of death, kidney transplantation and dialysis as competing events during five years after recovery of kidney function (RKF).